文献速递认知障碍与痴呆神经免疫

FDA批准首个神经退行性疾病疾病修饰疗法对后续临床试验设计的影响

Implications of FDA Approval of a First Disease-Modifying Therapy for a Neurodegenerative Disease on the Design of Subsequent Clinical Trials.
PubMed 文献 · Neurology · 2021-06-04

本文探讨在首个疾病修饰疗法获批后,神经退行性疾病后续临床试验设计中的争议,特别是安慰剂对照的使用。作者参考多发性硬化药物开发经验,分析三种设计方案的伦理与实践问题,并展望阿尔茨海默病临床试验的未来。

要点

  • 首个疾病修饰疗法获批后,后续试验需权衡更有效、更安全或更方便的治疗。
  • 争议核心在于安慰剂对照的使用,涉及三种设计:无新药安慰剂对照、以获批药为背景的安慰剂对照、以及新药作为活性对照。
  • 多发性硬化药物开发经验可为阿尔茨海默病等神经退行性疾病试验设计提供参考。

核心结论

  • 首个疾病修饰疗法获批后,后续临床试验设计需在伦理与实践间平衡,安慰剂对照的使用将引发争议。

研究设计与样本

  • 本文为综述性文章,基于多发性硬化药物开发经验,分析三种临床试验设计并讨论阿尔茨海默病的未来。

主要发现

  • 在无疾病减缓疗法的进展性神经退行性疾病中,首个疾病修饰治疗终将获批,但后续仍需试验发现更有效、更安全或更方便的治疗。

临床怎么用

  • 临床研究应参考多发性硬化等领域的经验,审慎选择安慰剂对照或活性对照设计以评估新疗法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The goal of clinical research is to improve clinical practice. In progressive neurodegenerative conditions without any disease-slowing therapies, this will result in eventual approval of a first disease-modifying treatment. Clinical trials will still be needed to discover treatments that are more effective, safer, or more convenient. This will generate controversies over how to design these trials; specifically, controversies about the use of a placebo control. We consider ethical guidance for these studies with attention to 3 designs: placebo-controlled trials in the absence of the new drug, placebo-controlled trials with the approved drug as background therapy, and trials with the new drug as an active control. To understand the practical implications of these designs, we examine experiences in drug development in multiple sclerosis. We conclude by contemplating the future of clinical trials in Alzheimer disease.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Grill JD, Karlawish J. Implications of FDA Approval of a First Disease-Modifying Therapy for a Neurodegenerative Disease on the Design of Subsequent Clinical Trials. Neurology. 2021. PMID: 34088880. doi:10.1212/WNL.0000000000012329

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。